Prevalence of community-acquired and nosocomial infections in hospitalized patients with systemic lupus erythematosus

Lupus

Volumn 19, Issue 1, 2010, Pages 43-48

  Navarro Zarza, J E ^a   A Hernandez E ^a   Casasola Vargas, J C ^a   Estrada Castro, E ^a   Burgos Vargas, R ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Community acquired infections; Nosocomial infections; Systemic lupus erythematosus

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; BETA LACTAM ANTIBIOTIC; CYCLOPHOSPHAMIDE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; BACTERIUM IDENTIFICATION; COMMUNICABLE DISEASE; COMMUNITY ACQUIRED PNEUMONIA; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG RESPONSE; DRUG USE; FEMALE; FEVER; GRAM NEGATIVE BACTERIUM; HOSPITAL INFECTION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION RISK; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; URINARY TRACT INFECTION;

EID: 74849104350     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203309345776     Document Type: Article

References (31)

1. Klippel JH Systemic Lupus Erythematosus: Demographics, prognosis, and outcome. J Rheumatol 1997 ; 48 (Suppl): 67-71.
2. Doria A., Iaccarino L., Ghirardello A., et al. Long-Term prognosis and causes of death in systemic lupus erythematosus. Am J Med 2006 ; 119: 700-706.
3. Abu-Shakra M., Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus results from a single center. I. Causes of death. J Rheumatol 1995 ; 22: 1259-1264.
4. Uramoto KM, Michet CJ, Thumboo J., Sunku J., OFallon WM, Gabriel SE Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum 1999 ; 42: 46-50.
5. Urowitz MB, Gladman DD, Abu-Shakra M., Farewell VT Mortality studies in systemic lupus erythematosus. III. Improved survival over 24 years. J Rheumatol 1997 ; 24: 1061-1065.
6. Bouza E., Moya JG, Mu±oz P. Infections in systemic lupus erythematosus and rheumatoid arthritis. Infect Dis Clin North Am 2001 ; 15: 335-361.
7. Petri M. Infections in systemic lupus erythematosus. Rheum Dis Clin North Am 1998 ; 24: 423-456.
8. Iliopoulos AG, Tsokos CG Immunopathogenesis and spectrum of infections in systemic lupus erythematosus. Semin Arthritis Rheum 1996 ; 25: 318-336.
9. Ter Borg EJ, Horst G., Limburg PC, van Rijswijk MH, Kallenberg CG C-reactive protein levels during disease exacerbations and infections in systemic lupus erythematosus: a prospective longitudinal study. J Rheumatol 1990 ; 17: 1642-1648.
10. Trager J., Ward MM Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheumatol 2001 ; 13: 345-351.
11. Gladman DD, Hussain F., IbÁ±ez D., Urowitz MB The nature and outcome of infection in systemic lupus erythematosus. Lupus 2002 ; 11: 234-239. (Pubitemid 34506728)
12. Zonana-Nacach A., Camargo-Coronel A., Ya±ez P., SÁnchez L., JimÉnez- Balderas FJ, Fraga A. Infections in outpatients with systemic lupus erythematosus: a prospective study. Lupus 2001 ; 10: 505-510.
13. Bosch X., Guilabert A., PallarÉs L., et al. Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients. Lupus 2006 ; 15: 584-589.
14. Kang I., Park SH Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol 2003 ; 15: 528-534.
15. Pryor BD, Bologna SG, Kahl LE Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum 1996 ; 39: 1475-1482.
16. Watanabe DKN, Duffy CM, Gladman DD Infection and disease activity in systemic lupus erythematosus: A review of hospitalized patients. J Rheumatol 1991 ; 18: 1180-1184.
17. Tan EM, Cohen AS, Fries JF, et al. The l982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982 ; 25: 1271-1277.
18. Graffar M. Une methode de classification sociale d echantillons de population. Courrier VI 1956 ; 445-459.
19. Valenzuela Yuraidini J., Diaz Andrade E., Klagges Valenzuela B. Clasificación social y estado nutritivo. Empleo de un nuevo método de clasificación social. Cuadernos Medico Sociales 1976 ; XVIII: 1.
20. Bombardier C., Gladman DD, Urowitz MB, Caron D., Chang CH Derivation of the SLEDAI. A disease activity index for Lupus patients. The Committee on prognosis studies in SLE. Arthritis Rheum 1992 ; 35: 630-640.
21. GuzmÁn J., Cardiel MH, Arce-Salinas A., et al. Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol 1992 ; 19: 1551-1558.
22. Gladman D., Glinzler E., Goldsmith C., et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for Systemic Lupus Erythematosus. Arthritis Rheum 1996 ; 39: 363-369.
23. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM CDC definitions for nosocomial infections. Am J Infect Control 1988 ; 16: 128-140.
24. AlarcÓn GS, McGwin G Jr, Bastian HM, et al. Systemic lupus erythematosus in three ethnic groups. VIII. Predictors of early mortality in the LUMINA cohort. Arthritis Car Res 2001 ; 45: 191-202.
25. Pons-Estel BA, Catoggio LJ, Cardiel MH, et al. The GLADEL multinational Latin American prospective inception cohort of 1214 patients with systemic lupus erythematosus. Ethnic and disease heterogeneity among Hispanics . Medicine 2004 ; 83: 1-17.
26. Fox RA, Isenberg DA Human immunodeficiency virus infection in systemic lupus erythematosus. Arthritis Rheum 1997 ; 40: 1168-1172.
27. Qui±Ónez-Alvarez MS,á-HernÁndez E., GonzÁlez-Chavez A., VelÁzquez-Moreno J. Prueba de ELISA falsa-positiva para Virus de la Inmunodeficiencia Humana en un paciente con lupus eritematoso sistÉmico. Rev Med Hosp Gen Mex 2006 ; 69: 216-220.
28. HernÁndez-Cruz B., Sifuentes-Osornio J., Ponce de LeÓn RS, Ponce de LeÓn GA, Díaz-Jouanen E. Mycobacterium tuberculosis infection in patients with systemic rheumatic diseases. A case series. Clin Exp Rheumatol 1999 ; 17: 289-296. (Pubitemid 29265675)
29. AlarcÓn GS Infections in systemic connective tissue diseases: Systemic lupus erythematosus, scleroderma, and polymyositis/dermatopolymyositis. Infect Dis Clin N Am 2006 ; 20: 849-875.
30. Nived O., Sturfelt G., Wollheim F. Systemic lupus erythematosus and infection: a controlled and prospective study including an epidemiological group. Q J Med 1985 ; 55: 271287.
31. Ginzler E., Diamond H., Kaplan D., et al. Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus. Arthritis Rheum 1978 ; 21: 37-44.